Innoveren Scientific Inc.
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage. It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023. The company is headquartered in Tampa, Florida.
Innoveren Scientific Inc. (IVRN) - Net Assets
Latest net assets as of September 2023: $-10.89 Million USD
Based on the latest financial reports, Innoveren Scientific Inc. (IVRN) has net assets worth $-10.89 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($789.32K) and total liabilities ($11.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-10.89 Million |
| % of Total Assets | -1379.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Innoveren Scientific Inc. - Net Assets Trend (2019–2022)
This chart illustrates how Innoveren Scientific Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innoveren Scientific Inc. (2019–2022)
The table below shows the annual net assets of Innoveren Scientific Inc. from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-9.36 Million | -100.71% |
| 2021-12-31 | $-4.66 Million | -344.94% |
| 2020-12-31 | $-1.05 Million | +69.18% |
| 2019-12-31 | $-3.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innoveren Scientific Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2196546200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $49.97 Million | % |
| Total Equity | $-9.36 Million | 100.00% |
Innoveren Scientific Inc. Competitors by Market Cap
The table below lists competitors of Innoveren Scientific Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EASTFIELD RES
BE:35E
|
$130.33 |
|
DFNN Inc
PSE:DFNN
|
$130.46 |
|
PT Medela Potentia Tbk
JK:MDLA
|
$130.48 |
|
KWG PROPERTY (KOU.SG)
STU:KOU
|
$131.02 |
|
Unicap Modaraba
KAR:UCAPM
|
$130.12 |
|
W.A.G payment solutions plc
LSE:EWG
|
$130.04 |
|
CVR Medical Corp
STU:B3BN
|
$129.66 |
|
Brite-Strike Tactical Illumination Products Inc
PINK:BSTK
|
$129.64 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innoveren Scientific Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -4,662,243 to -9,357,386, a change of -4,695,143.
- Net loss of 10,299,580 reduced equity.
- New share issuances of 254,999 increased equity.
- Other factors increased equity by 5,349,438.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.30 Million | -110.07% |
| Share Issuances | $255.00K | +2.73% |
| Other Changes | $5.35 Million | +57.17% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Innoveren Scientific Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-30.37 | $0.00 | x |
| 2020-12-31 | $-5.33 | $0.00 | x |
| 2021-12-31 | $-28.39 | $0.00 | x |
| 2022-12-31 | $-15.13 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innoveren Scientific Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2271.33%
- • Asset Turnover: 3.30x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -357.11% | 2.55x | 0.00x | $-29.50 Million |
| 2020 | 0.00% | -300.34% | 0.98x | 0.00x | $-6.39 Million |
| 2021 | 0.00% | -297.81% | 5.01x | 0.00x | $-4.33 Million |
| 2022 | 0.00% | -2271.33% | 3.30x | 0.00x | $-9.36 Million |
Industry Comparison
This section compares Innoveren Scientific Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innoveren Scientific Inc. (IVRN) | $-10.89 Million | 0.00% | N/A | $130.13 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |